Release Date:
August 12, 2022
Expiration Date:
August 12, 2023
Activity Overview
Medical Crossfire®, one of PER®’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirted discussions and debates on a particular clinical topic. In this activity, 3 key thought leaders explore the latest data regarding current and emerging therapeutic strategies for the management of Hodgkin lymphoma (HL) and T-cell lymphoma across lines of care. This lively discussion will help place new developments into clinical context to help you optimize care for your patients with HL or T-cell lymphoma.
Target Audience
This educational program is directed toward hematologists, oncologists, pharmacists, and nurses involved in the treatment and management of HL and PTCL.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
• Assess the efficacy and safety profile for current and emerging therapies among patients with advanced HL and PTCL from landmark clinical trials as well as real-world data in the frontline setting and beyond
• Discuss current and emerging salvage and consolidation/maintenance strategies that reduce the risk of recurrence in patients with HL undergoing ASCT
• Apply evidence from landmark trials in advanced HL and PTCL to real-world case scenarios in the management of patients with these hematologic malignancies
• Plan strategies for proactively recognizing, monitoring, and managing adverse events associated with the use of novel therapies in the management of patients with HL and PTCL
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
